Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of “Buy” by Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average rating of “Buy” by the ten research firms that are presently covering the company, Marketbeat reports. Ten analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $67.75.

A number of equities analysts recently issued reports on the company. HC Wainwright decreased their target price on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Royal Bank of Canada dropped their price target on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock.

Institutional Trading of Jasper Therapeutics

Several institutional investors have recently made changes to their positions in JSPR. Rhumbline Advisers purchased a new stake in Jasper Therapeutics in the 2nd quarter worth approximately $300,000. American Century Companies Inc. increased its stake in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after acquiring an additional 3,032 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Jasper Therapeutics during the third quarter worth $59,000. Fernwood Investment Management LLC grew its stake in Jasper Therapeutics by 6.9% in the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after purchasing an additional 3,427 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in Jasper Therapeutics in the 3rd quarter worth about $329,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Trading Up 15.9 %

NASDAQ:JSPR opened at $6.70 on Friday. The company has a 50-day moving average of $16.47 and a 200-day moving average of $18.65. The firm has a market cap of $100.50 million, a price-to-earnings ratio of -1.41 and a beta of 2.18. Jasper Therapeutics has a twelve month low of $5.25 and a twelve month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, November 7th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15). On average, research analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.